Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma

BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against multiple myeloma, yet antigen escape and tumor relapse still occur after the use of these therapies. Designing CAR-T therapies that targets multiple antigens simultaneously seems a feasible w...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yaru, Liu, Xiuying, Li, Xiaorui, Zhou, Yating, Song, Zhiru, Zhang, Jing, Shi, Bingjie, Wang, Jianxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381848/
https://www.ncbi.nlm.nih.gov/pubmed/34434610
http://dx.doi.org/10.1080/2162402X.2021.1959102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381848/
https://www.ncbi.nlm.nih.gov/pubmed/34434610
http://dx.doi.org/10.1080/2162402X.2021.1959102

Ejemplares similares